BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24977485)

  • 1. Sphingolipids: important players in multiple sclerosis.
    Halmer R; Walter S; Faßbender K
    Cell Physiol Biochem; 2014; 34(1):111-8. PubMed ID: 24977485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spingolipids in Multiple Sclerosis.
    Walter S; Fassbender K
    Cell Physiol Biochem; 2010; 26(1):49-56. PubMed ID: 20502004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
    Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis.
    Podbielska M; Krotkiewski H; Hogan EL
    Neurochem Res; 2012 Jun; 37(6):1154-69. PubMed ID: 22451227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
    Hla T; Brinkmann V
    Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
    Groves A; Kihara Y; Chun J
    J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
    Kipp M; Amor S
    Mult Scler; 2012 Mar; 18(3):258-63. PubMed ID: 22383435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of sphingosine 1-phosphate modulation on immune outcomes.
    Pinschewer DD; Brinkmann V; Merkler D
    Neurology; 2011 Feb; 76(8 Suppl 3):S15-9. PubMed ID: 21339486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod therapy for multiple sclerosis.
    Willis MA; Cohen JA
    Semin Neurol; 2013 Feb; 33(1):37-44. PubMed ID: 23709211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors.
    Delgado A; Martínez-Cartro M
    Curr Med Chem; 2016; 23(3):242-64. PubMed ID: 26639095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
    Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
    Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second generation S1P pathway modulators: research strategies and clinical developments.
    Bigaud M; Guerini D; Billich A; Bassilana F; Brinkmann V
    Biochim Biophys Acta; 2014 May; 1841(5):745-58. PubMed ID: 24239768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
    van Doorn R; Nijland PG; Dekker N; Witte ME; Lopes-Pinheiro MA; van het Hof B; Kooij G; Reijerkerk A; Dijkstra C; van van der Valk P; van Horssen J; de Vries HE
    Acta Neuropathol; 2012 Sep; 124(3):397-410. PubMed ID: 22810490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingosine 1-phosphate pathway therapeutics: a lipid ligand-receptor paradigm.
    Rosen H; Liao J
    Curr Opin Chem Biol; 2003 Aug; 7(4):461-8. PubMed ID: 12941420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
    Tar L; Vécsei L
    Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
    Spampinato SF; Obermeier B; Cotleur A; Love A; Takeshita Y; Sano Y; Kanda T; Ransohoff RM
    PLoS One; 2015; 10(7):e0133392. PubMed ID: 26197437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW; Choi JW; Chun J
    Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    Massberg S; von Andrian UH
    N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.